Sun Pharma's Acquisition

Sun Pharma Makes Bold $11.75 Billion Move to Acquire Organon

In one of the largest deals in the pharmaceutical industry recently, Indian pharmaceutical giant Sun Pharmaceutical Industries, signed a definitive agreement to acquire Organon & Co. In what is shaping up to be one of the largest transactions in the pharmaceutical space of late, India-headquartered Sun Pharmaceutical Industries has signed a definitive agreement to purchase Organon & Co. Of Jersey City, New Jersey, a company focused on women’s health, all-cash, for $14 per Organon share. The deal price comes in at $11.75 billion.

Organon itself is one relatively young entity that spun off from the giant pharma company Merck in 2021. In the years that followed, Organon slowly but surely built itself a rather significant commercial presence, currently boasting a portfolio of over 70 products, across categories of women’s health products, biosimilars and general medicines which are sold in some 140 countries. Its main markets include the US, Europe, China, Canada and Brazil, and its six manufacturing plants are strategically distributed across the European Union and key emerging markets.

For Sun Pharma this is all part of its long-term strategic transformation towards higher margin innovative medicines and Organon provides a direct acceleration tool towards those objectives. But most importantly, this gives Sun Pharma a strong, credible entry into global biosimilars, a segment that is projected to grow to $100 billion by the early 2030s, in what will be a time of multiple patents expiring. Sun Pharma is set to rank as the 10th player in global biosimilars, post deal closing.

Beyond biosimilars, the company also would become one of the top three global players in women’s health, a historically under-resourced field when looked against its global disease burden, and in which Sun Pharma obtains established, already developed products, commercial relationships and distribution networks through the deal. On a broader financial level, the resulting entity would have revenues of $12.4 billion making it one of the top 25 pharma companies globally, EBITDA and cash flows roughly double those of Sun Pharma as standalone entity and its commercial presence expanding to 150 countries, with 18 individual markets expected to deliver over $100 million in annual sales each.

Organon’s standalone financial position on the signing of the deal signals mixed potential. The company reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for the full year 2025 but with debt standing at $8.6 billion, with just $574 million of cash on hand. A recently concluded product divestment expected to yield $440 million, should see cash improve somewhat by the closing.

Boards of both companies have approved the transaction, and the consummation is conditional upon approval by Organon shareholders and various regulatory approvals in jurisdictions relevant, possibly raising some questions from antitrusters in the US, EU and possibly China due to the overlapping market coverage. This deal is expected to close early 2027.